Diving into the Efficacy & Tolerability of mBC Treatment
Pavani Chalasani, MD, MPH
Colleen Bohnenkamp, PharmD, BCPS, BCOP
Reducing the Rise of Uterine Cancer in the United States
Charles Turck, PharmD, BCPS, BCCCP
Richard T. Penson, MD, MRCP
Contextualizing the Evidence in Lymphomas: ADCs and Bispecific Antibodies in HL, FL, and DLBCL
John P. Leonard, MD
Matthew J. Matasar, MD
Alex Herrera, MD
Kami Maddocks, MD
Alison J. Moskowitz, MD
Sarah Rutherford, MD
Antibody-Drug Conjugates in FL
First-Line Treatment of Adults with Classical Hodgkin Lymphoma
Patient Selection for ADCs in First-Line DLBCL
Individualizing Frontline Treatment
Application of Data from the ECHELON-1 Trial
NCCN Guideline Updates in DLBCL
Clinical Implications of Bispecific Antibodies and Antibody-Drug Conjugates in FL
Late-Stage Bispecifics and ADCs in DLBCL
Bispecific Antibodies in FL
Study Shows Importance of Comprehensive Genomic Profiling for NSCLC
Vivek Subbiah, MD
Impact of Infertility & Elective Fertility Among Female Oncologists
Emily MacDuffie, MD
Combating the Complexities of Cancer Care During Pregnancy
Alison Wakoff Loren, MD, MSCE
Optimizing Quality & Safety Systems to Reduce the Risk of Patient Harm
Jacob Sands, MD
Joseph O. Jacobson, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.